Skip to main content
. 2016 Dec 1;8(3):5038–5047. doi: 10.18632/oncotarget.13766

Figure 1. miR106a overexpression in CRC clinical samples.

Figure 1

A. Quantification of miR106a mRNA expression in CRC tissues and non-tumor tissues. **P<0.01, compared with non-tumor counterpart. B. Kaplan-Meier analysis of overall survival in 138 patients based on the tumor level of miR106a expression. The overall survival of the high miR106a patients(n=84) was significantly worse than that of the low miR106a patients (n=54), and p=0.0219. C. Kaplan-Meier analysis of disease-free survival in 138 patients. The prognostic value of miR106a is not significant (p=0.491). The log-rank test was used to calculate p-values.